Supplementary Material

Safety, tolerability, and pharmacokinetics of subcutaneous extended-release injectable olanzapine in patients with schizophrenia and schizoaffective disorder

Authors: Irina Cherniakov, Avia Merenlender Wagner, Roy Eshet, Ryan Tiver, David Bibi, Itay Perlstein, Attila Kalmanczhelyi, Nir Sharon, Gadi Cohen, Kristina Ferderber, James Roberts, Anna Elgart, Dikla Gutman, Laura Rabinovich-Guilatt

Corresponding author: Irina Cherniakov; Teva Pharmaceutical Industries Ltd., Netanya, Israel; Irina.Cherniakov@teva.co.il

Table S1 Baseline demographic information for enrolled patients

	Patients with schizophrenia or schizoaffective disorder[a]						
	SD TV-44749				**MD TV-44749**		
	Overall[b] (*N* = 54)	**318 mg** (*n* = 17)	**425 mg** (*n* = 20)	**531 mg** (*n* = 17)	**Overall[b]** (*N* = 37)	**283 mg** (*n* = 16)	**566 mg** (*n* = 21)
Sex, *n* (%)							
Male	41 (76)	12 (71)	14 (70)	15 (88)	29 (78)	11 (69)	18 (86)
Race, *n* (%)							
White	7 (13)	1 (6)	3 (15)	3 (18)	8 (22)	2 (13)	6 (29)
Black	47 (87)	16 (94)	17 (85)	14 (82)	28 (76)	13 (81)	15 (71)
Age, mean (Std Dev), years	43.9 (9.9)	39.8 (9.8)	45.7 (9.9)	46.0 (9.4)	47.8 (11.02)	46.0 (11.9)	49.2 (10.4)
Weight, mean (Std Dev), kg	89.4 (14.49)	87.8 (12.1)	92.6 (14.4)	87.3 (16.9)	83.4 (16.52)	79.8 (16.4)	86.2 (16.5)
Smoker, *n* (%)	46 (85)	14 (82)	17 (85)	15 (88)	26 (70)	13 (81)	13 (62)

DSM-5 Diagnostic and Statistical Manual of Mental Disorders Fifth Edition, *MD* multiple-dose, *PK* pharmacokinetic, *SD* single-dose, *Std Dev* standard deviation

[a]All patients were required to have a DSM-5–confirmed diagnosis of schizophrenia, be clinically stable, and not currently be on antipsychotic treatment other than oral olanzapine

[b]The PK analysis population included 71 patients (SD, 42; MD, 29)

Table S2 Relative bioavailability at steady state of TV-44749 as compared to oral olanzapine

	TV-44749 (test)	**Oral olanzapine (reference)**	**Geo LS mean ratio (%)**	**90% CI of ratio**
Parameter (unit)	Geo mean	Geo mean	(test/reference)	(test/reference)
Dose-normalized AUC_{τ} ([h*ng/mL]/mg)[a]	46.88	49.25	0.95	0.855, 1.059

AUC area under the plasma concentration–time curve, AUC_{0-tau} area under the plasma concentration–time curve from time 0 to the end of the dosing interval, *CI* confidence interval, *Geo* geometric, *LS* least squares

[a]The relative bioavailability was evaluated for olanzapine dose-normalized AUC (ln-transformed AUC_{0-tau} [TV-44749] for the third TV-44749 multiple-dosing 28-day interval and dose-normalized ln-transformed $AUC_{0\text{-}tau,ss*28d}$,calculated for oral olanzapine, both of which reflect the steady-state AUC over 28 days and treated as one outcome)

Table S3 Adverse events leading to withdrawal

MedDRA preferred term, *n* (%)	Study treatment		
	Oral olanzapine (*N* = 127)	**SD TV-44749 (*N* = 42)**	**MD TV-44749 (*N* = 29)**
Patients with ≥1 AE leading to study withdrawal	4 (3.1)	1 (2.4)	0 (0)
Neutropenia	1 (0.8)	0 (0)	0 (0)
Low-density lipoprotein increased	2 (1.6)	0 (0)	0 (0)
Rash	1 (0.8)	0 (0)	0 (0)
Psychotic disorder	0 (0)	1 (2.4)[a]	0 (0)

AE adverse event, *MedDRA* Medical Dictionary for Regulatory Activities, *MD* multiple-dose, *SD* single-dose

[a]Patient received TV-44749 425 mg